Clinical Trial Update: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity, reactogenicity and safety of a combined Measles, Mumps and Rubella vaccine produced by Bio-Manguinhos/Fiocruz in childr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• Measles, Mumps and Rubella Vaccine (Bio-Manguinhos/Fiocruz) (Measles, Mumps and Rubella vaccine)
• Tetraviral Vaccine (Tetravalent vaccine containing measles, mumps, rubella and varicella)

Snippet

Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Conditions: Measles, Mumps | Phase 3 | Status: COMPLETED